Constructive Outcomes from Part 3 BouNDless Trial of Investigational ND0612 in Folks with Parkinson’s Illness Experiencing Motor Fluctuation

JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) in the present day introduced the publication of leads to The Lancet Neurology from the pivotal, Part 3 BouNDless trial (NCT04006210) evaluating the efficacy, security and tolerability of investigational ND0612 – a steady, 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) – compared to oral immediate-release (IR) LD/CD in folks with Parkinson’s illness (PD) experiencing motor fluctuations. Outcomes from the examine, which met its major endpoint and the primary 4 secondary endpoints, confirmed ND0612 was superior at growing “ON” time with out troublesome dyskinesia and decreasing “OFF” time, in comparison with oral IR-LD/CD after 12 weeks.

“Orally administered levodopa/carbidopa tablets stay probably the most important pharmacological intervention in Parkinson’s illness; nonetheless, over time, the reliability of its advantages can lower, resulting in the onset of motor fluctuations,” mentioned Professor Alberto Espay, Principal U.S. Investigator of the BouNDless trial and Director of the James J. and Joan A. Gardner Household Heart for Parkinson’s Illness and Motion Issues on the College of Cincinnati. “We’re inspired by these constructive knowledge, which we consider assist ND0612, if authorized, as a possible remedy possibility for folks with Parkinson’s illness experiencing motor fluctuations who’ve to this point had restricted choices.”

Examine individuals entered an open label IR-LD/CD optimization part adopted by an open label ND0612 plus IR-LD/CD optimization part and have been then randomized to a 12-week double-blind double-dummy (DBDD) remedy interval with both ND0612 or oral IR-LD/CD regimens. Key examine findings embody:

• Remedy with ND0612 demonstrated favorable efficacy with a statistically vital addition (p<0.0001) of 1.72 hours in “ON” time with out troublesome dyskinesia over oral IR-LD/CD, thus assembly the trial’s major endpoint.
• The trial additionally demonstrated constructive and clinically significant outcomes for the primary 4 secondary endpoints, together with the important thing secondary endpoint with a further 1.4-hour discount in day by day “OFF” time (p<0.0001) with ND0612 vs. oral IR-LD/CD.
• The remaining secondary endpoints that reached statistical significance have been the Motion Issues Society-Unified Parkinson’s Illness Ranking Scale (MDS-UPDRS) Half II scores (-3.05 [-4.28, -1.81], p<0.0001), the Sufferers World Impression of Change (Odds Ratio [OR]: 5.31 [2.67, 10.58], p<0.0001) and Clinician World Impression of Enchancment (OR: 7.23 [3.57, 14.64], p<0.0001).
• The systemic security profile of ND0612 was in keeping with the well-established security profile of oral normal of care LD/CD. Infusion web site reactions (ISRs) have been probably the most reported remedy emergent opposed occasions (TEAEs) in any group throughout the DBDD interval (57% for ND0612 vs. 43% for IR-LD/CD).
• Some ISRs (infusion web site nodule, infusion web site bruising, infusion web site an infection, infusion web site erythema, infusion web site ache, infusion web site eschar and infusion web site swelling) have been extra frequent within the ND0612 group in comparison with placebo and oral LD/CD teams. Moreover, solely 6% of examine individuals discontinued the trial throughout the DBDD interval resulting from any motive – together with 5% resulting from AEs – in comparison with discontinuation charges of 6% and three%, respectively, of examine individuals within the oral LD/CD teams.

“These findings from the BouNDless examine present us that steady, subcutaneous supply of levodopa/carbidopa with ND0612 has the potential to influence folks residing with Parkinson’s illness who expertise motor fluctuations,” mentioned Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. “We stay up for the continued analysis of ND0612 to additional our understanding of its impact in Parkinson’s illness, and as part of our dedication to handle unmet wants for this affected person inhabitants.”

Analyses of outcomes from the continuing BouNDless trial complement the long-term security knowledge from the BeyoND examine (NCT02726386) assessing ND0612, with some sufferers of their eighth 12 months of follow-up.¹

About ND0612
ND0612 is an investigational drug-device mixture remedy – a 24-hours/day, steady subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the remedy of motor fluctuations in folks with Parkinson’s illness (PD). Improvement of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Company (MTPC). The protection and efficacy of ND0612 in PD is beneath evaluation by the U.S. Meals and Drug Administration (FDA), who has assigned a Prescription Drug Consumer Payment Act (PDUFA) goal motion date for the second quarter of CY (calendar 12 months) 2024.

About Mitsubishi Tanabe Pharma America, Inc.
Primarily based in Jersey Metropolis, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Company (MTPC). It was established by MTPC to develop and advance our pipeline in addition to commercialize authorized pharmaceutical merchandise in North America. For extra data, please go to www.mt-pharma-america.com or observe us on X (previously Twitter), Fb and LinkedIn.

About Mitsubishi Tanabe Pharma Company
Mitsubishi Tanabe Pharma Company (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is among the oldest pharmaceutical firms on this planet, based in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical trade. MCG has positioned well being care as its strategic focus in its administration coverage, “Forging the longer term”. MTPC units the MISSION of “Creating hope for all going through sickness”. To that finish, MTPC is engaged on the illness areas of central nervous system, immuno-inflammation, diabetes and kidney, and most cancers. MTPC is specializing in “precision medication” to offer medication with excessive remedy satisfaction and moreover working to develop “across the tablet options” to handle particular affected person issues based mostly on therapeutic medication, together with prevention of illnesses, pre-symptomatic illness care, prevention of aggravation and prognosis.

About NeuroDerm, Ltd.
NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Company (MTPC), based mostly in Israel, impressed to cut back illness burden and enhance the standard of life of sufferers and their households via modern drug-device mixture therapies and applied sciences. NeuroDerm is an built-in pharmaceutical and medical expertise firm growing central nervous system (CNS) product candidates.

1. S Isaacson, et al. Lengthy-term security of steady levodopa/carbidopa infusion with ND0612: Outcomes from the continuing BeyoND examine. Poster introduced at: American Academy of Neurology Annual Assembly; 2022 Apr 2-7; Seattle, WA.

SOURCE Mitsubishi Tanabe Pharma America

Posted: March 2024

Extra information sources

Subscribe to our publication

No matter your matter of curiosity, subscribe to our newsletters to get the very best of Medication.com in your inbox.